Completed PHASE3 INTERVENTIONAL 1-arm NCT00904449

Open Label Assessment of Long-Term Safety and Utility

An Open-Label Assessment of the Long-Term Safety and Utility of Numorphan® for the Relief of Moderate to Severe Pain in Patients With Cancer

Sponsor: Endo Pharmaceuticals

Conditions Pain

Interventions Oxymorphone ER

Updated 7 times since 2017 Last updated: Feb 9, 2010 Started: Apr 30, 2001 Primary completion: Dec 31, 2002 Completion: Dec 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Pain and is currently completed. Endo Pharmaceuticals leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Endo Pharmaceuticals

Data source: Endo Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.